Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people

作者：Tracey Sach, Mary Onoja, Holly Clarke, Miriam Santer, Ingrid Müller, Taeko Becque, Beth Stuart, Julie Hooper, Mary Steele, Sylvia Wilczynska, Matthew J Ridd, Amanda Roberts, Amina Ahmed, Lucy Yardley, Paul Little, Kate Greenwell, Katy Sivyer, Jacqui Nuttall, Gareth Griffiths, Sandra Lawton, Sinéad Langan, Laura Howells, Paul Leighton, Hywel C Williams, Kim S Thomas · 发表于：The European Journal of Health Economics · 年份：2024 · DOI：10.1007/s10198-023-01649-9 · 被引用次数：5 · 研究领域：Dermatology and Skin Diseases、Psoriasis: Treatment and Pathogenesis、Allergic Rhinitis and Sensitization

OBJECTIVE: To estimate the cost-effectiveness of online behavioral interventions (EczemaCareOnline.org.uk) designed to support eczema self-care management for parents/carers and young people from an NHS perspective. METHODS: Two within-trial economic evaluations, using regression-based approaches, adjusting for baseline and pre-specified confounder variables, were undertaken alongside two independent, pragmatic, parallel group, unmasked randomized controlled trials, recruiting through primary care. Trial 1 recruited 340 parents/carers of children aged 0-12 years and Trial 2 337 young people aged 13-25 years with eczema scored ≥ 5 on Patient-Oriented Eczema Measure (POEM). Participants were randomized (1:1) to online intervention plus usual care or usual care alone. Resource use, collected via medical notes review, was valued using published unit costs in UK £Sterling 2021. Quality-of-life was elicited using proxy CHU-9D in Trial 1 and self-report EQ-5D-5L in Trial 2. RESULTS: The intervention was dominant (cost saving and more effective) with a high probability of cost-effectiveness (> 68%) in most analyses. The exception was the complete case cost-utility analysis for Trial 1 (omitting participants with children aged < 2), with adjusted incremental cost savings of -£34.15 (95% CI - 104.54 to 36.24) and incremental QALYs of - 0.003 (95% CI - 0.021 to 0.015) producing an incremental cost per QALY of £12,466. In the secondary combined (Trials 1 and 2) cost-effectiveness analysi...